Female Hypoactive Sexual Desire Disorder - Pipeline Review, H2 2018

Global Markets Direct’s, ‘Female Hypoactive Sexual Desire Disorder - Pipeline Review, H2 2018’, provides an overview of the Female Hypoactive Sexual Desire Disorder pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Female Hypoactive Sexual Desire Disorder, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Female Hypoactive Sexual Desire Disorder and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Female Hypoactive Sexual Desire Disorder

- The report reviews pipeline therapeutics for Female Hypoactive Sexual Desire Disorder by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved Female Hypoactive Sexual Desire Disorder therapeutics and enlists all their major and minor projects

- The report assesses Female Hypoactive Sexual Desire Disorder therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news related to pipeline therapeutics for Female Hypoactive Sexual Desire Disorder

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Female Hypoactive Sexual Desire Disorder

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Female Hypoactive Sexual Desire Disorder pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Dare Bioscience Inc

Emotional Brain BV

EndoCeutics Inc

Fabre-Kramer Pharmaceuticals Inc

Kuhnil Pharmaceutical Co Ltd

Palatin Technologies Inc

Pivot Pharmaceuticals Inc

S1 Biopharma Inc

Dare Bioscience Inc

Emotional Brain BV

EndoCeutics Inc

Fabre-Kramer Pharmaceuticals Inc

Kuhnil Pharmaceutical Co Ltd

Palatin Technologies Inc

Pivot Pharmaceuticals Inc

S1 Biopharma Inc

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Female Hypoactive Sexual Desire Disorder - Overview

Female Hypoactive Sexual ...

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Female Hypoactive Sexual Desire Disorder - Overview

Female Hypoactive Sexual Desire Disorder - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Female Hypoactive Sexual Desire Disorder - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Female Hypoactive Sexual Desire Disorder - Companies Involved in Therapeutics Development

Dare Bioscience Inc

Emotional Brain BV

EndoCeutics Inc

Fabre-Kramer Pharmaceuticals Inc

Kuhnil Pharmaceutical Co Ltd

Palatin Technologies Inc

Pivot Pharmaceuticals Inc

S1 Biopharma Inc

Female Hypoactive Sexual Desire Disorder - Drug Profiles

(buspirone hydrochloride + testosterone) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(sildenafil citrate + testosterone) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BP-101 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

bremelanotide - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

gepirone hydrochloride ER - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

KI-1120 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

prasterone - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PVT-005 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PVT-011 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

sildenafil citrate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SIP-104 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Female Hypoactive Sexual Desire Disorder - Dormant Projects

Female Hypoactive Sexual Desire Disorder - Product Development Milestones

Featured News & Press Releases

Jun 27, 2018: Pivot Pharma To File Investigational New Drug Application With U.S. FDA For PVT-005

Jun 04, 2018: AMAG Pharmaceuticals Announces FDA Acceptance of New Drug Application Filing for Bremelanotide

Jun 04, 2018: Palatin Technologies Announces FDA Acceptance for Review of Bremelanotide NDA

Mar 26, 2018: AMAG Pharmaceuticals Submits a New Drug Application to the U.S. Food and Drug Administration for Bremelanotide for the treatment of Hypoactive Sexual Desire Disorder in Premenopausal Women

Jan 09, 2018: Emotional Brain FSIAD Product Lybridos shows High Efficacy and Safety in Phase 2B Trials

Jan 09, 2018: Emotional Brain's FSIAD Product Lybrido shows High Efficacy and Safety in Phase 2B Trials

Mar 20, 2017: Palatin Technologies Receives Notice of Allowance on Bremelanotide Methods of Use Patent for Treatment of Hypoactive Sexual Desire Disorder in Premenopausal Women

Feb 27, 2017: AMAG and Palatin Announce Rekynda Data Presentations at the International Society for the Study of Women’s Sexual Health Annual Meeting

Nov 01, 2016: Bremelanotide Meets Co-Primary Endpoints in Palatins Phase 3 Trials for Hypoactive Sexual Desire Disorder

Sep 23, 2016: Palatin Technologies Presents Bremelanotide Neurobiology and Treatment Efficacy Review at World Meeting on Sexual Medicine

Aug 04, 2016: Palatin Technologies Announces Completion of All Patient Visits In Phase 3 Clinical Trials of Bremelanotide for Hypoactive Sexual Desire Disorder

Nov 02, 2015: Nicolas Sitchon, CEO of S1 Biopharma, to Present at BIO-Europe 2015 Conference

Aug 20, 2015: S1 Biopharma Supports FDA Approval of First-Ever Treatment for Hypoactive Sexual Desire Disorder

May 01, 2015: Emotional Brain Prepares for the Last Stage in Clinical Development of Medicines for Sexual Dysfunction in Women

Jul 29, 2013: S1 Biopharma Doses First Patients in Phase 2a Clinical Trial of Lorexys in Premenopausal Women with HSDD

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Female Hypoactive Sexual Desire Disorder, H2 2018

Number of Products under Development by Companies, H2 2018 ...

List of Tables

Number of Products under Development for Female Hypoactive Sexual Desire Disorder, H2 2018

Number of Products under Development by Companies, H2 2018

Products under Development by Companies, H2 2018

Number of Products by Stage and Target, H2 2018

Number of Products by Stage and Mechanism of Action, H2 2018

Number of Products by Stage and Route of Administration, H2 2018

Number of Products by Stage and Molecule Type, H2 2018

Female Hypoactive Sexual Desire Disorder - Pipeline by Dare Bioscience Inc, H2 2018

Female Hypoactive Sexual Desire Disorder - Pipeline by Emotional Brain BV, H2 2018

Female Hypoactive Sexual Desire Disorder - Pipeline by EndoCeutics Inc, H2 2018

Female Hypoactive Sexual Desire Disorder - Pipeline by Fabre-Kramer Pharmaceuticals Inc, H2 2018

Female Hypoactive Sexual Desire Disorder - Pipeline by Kuhnil Pharmaceutical Co Ltd, H2 2018

Female Hypoactive Sexual Desire Disorder - Pipeline by Palatin Technologies Inc, H2 2018

Female Hypoactive Sexual Desire Disorder - Pipeline by Pivot Pharmaceuticals Inc, H2 2018

Female Hypoactive Sexual Desire Disorder - Pipeline by S1 Biopharma Inc, H2 2018

Female Hypoactive Sexual Desire Disorder - Dormant Projects, H2 2018

List of Figures

List of Figures

Number of Products under Development for Female Hypoactive Sexual Desire Disorder, H2 2018

Number of Products under Development by Companies, H2 2018 ...

List of Figures

Number of Products under Development for Female Hypoactive Sexual Desire Disorder, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products by Top 10 Targets, H2 2018

Number of Products by Stage and Top 10 Targets, H2 2018

Number of Products by Top 10 Mechanism of Actions, H2 2018

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2018

Number of Products by Routes of Administration, H2 2018

Number of Products by Stage and Routes of Administration, H2 2018

Number of Products by Molecule Types, H2 2018

Number of Products by Stage and Molecule Types, H2 2018

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports